GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
Rubican... AM I DIVERSIFIED.
I want you to look really carefully at the 3 second mark. Did this guy just join them walking up the street?Because the rest of the vid looks lily white..
I want you to look really carefully at the 3 second mark. Did this guy just join them walking up the street?Because the rest of the vid looks lily white..
Ouster LIDAR revealed!
It's people!!! It's PEOPLE!!!!!!
OMG-
It's people!!! It's PEOPLE!!!!!!
OMG-
Sept 15th->
Lava Therapeutics initiated with an Outperform at JMP Securities 09/15 LVTX JMP Securities analyst Reni Benjamin initiated coverage of Lava Therapeutics with an Outperform rating and $6.00 price target. The company's lead asset, LAVA-051, is generating encouraging early-stage clinical data in CLL and MM, while its second asset, LAVA-1207, has shown activity in preclinical models of prostate cancer and is being evaluated in Phase 1 clinical trials, the analyst tells investors in a research note. Benjamin adds that Lava Therapeutics shares represents a unique investment opportunity, with 19% potential downside and 428% potential upside.
Sept 26th->
Seagen, Lava Therapeutics announce exclusive LAVA-1223 license agreement 09/26 SGEN, LVTX Seagen (SGEN) and Lava Therapeutics (LVTX) announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced preclinical asset that utilizes LAVA's proprietary Gammabody technology to target epidermal growth factor receptor, or EGFR-expressing solid tumors. Under the terms of the agreement, Seagen will receive an exclusive global license for LAVA-1223 and pay LAVA $50M upfront; up to approximately $650M in potential development, regulatory and commercial milestones; and royalties ranging from the single digits to the mid-teens on future sales. The agreement also provides Seagen with the opportunity to exclusively negotiate rights to apply LAVA's proprietary Gammabody platform on up to two additional tumor targets.
Ok that's a 3rd compound! 1223 and they got $50 mln!
STOCK was $2.46 and ZOOMED To $4.60!
Corrected to $3.30 and now is $4.26.
Lava Therapeutics initiated with an Outperform at JMP Securities 09/15 LVTX JMP Securities analyst Reni Benjamin initiated coverage of Lava Therapeutics with an Outperform rating and $6.00 price target. The company's lead asset, LAVA-051, is generating encouraging early-stage clinical data in CLL and MM, while its second asset, LAVA-1207, has shown activity in preclinical models of prostate cancer and is being evaluated in Phase 1 clinical trials, the analyst tells investors in a research note. Benjamin adds that Lava Therapeutics shares represents a unique investment opportunity, with 19% potential downside and 428% potential upside.
Sept 26th->
Seagen, Lava Therapeutics announce exclusive LAVA-1223 license agreement 09/26 SGEN, LVTX Seagen (SGEN) and Lava Therapeutics (LVTX) announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced preclinical asset that utilizes LAVA's proprietary Gammabody technology to target epidermal growth factor receptor, or EGFR-expressing solid tumors. Under the terms of the agreement, Seagen will receive an exclusive global license for LAVA-1223 and pay LAVA $50M upfront; up to approximately $650M in potential development, regulatory and commercial milestones; and royalties ranging from the single digits to the mid-teens on future sales. The agreement also provides Seagen with the opportunity to exclusively negotiate rights to apply LAVA's proprietary Gammabody platform on up to two additional tumor targets.
Ok that's a 3rd compound! 1223 and they got $50 mln!
STOCK was $2.46 and ZOOMED To $4.60!
Corrected to $3.30 and now is $4.26.
Oh baby..... Is this the next DICE? the next MERX? The next KRTX...The Next... well you get the idea....
LAVA Therapeutics: Assessing A Promising Innovator
Oct. 18, 2022 2:32 AM ET LAVA Therapeutics N.V. (LVTX)
Summary
LAVA Therapeutics: Assessing A Promising Innovator
Oct. 18, 2022 2:32 AM ET LAVA Therapeutics N.V. (LVTX)
Summary
- LAVA is able to form a highly profitable partnership with Seagen to develop LAVA-1223 for various solid tumors.
- The company's Gammabody platform holds strong promises as a delivery vehicle for a differentiated type of cellular therapy.
- There is an upcoming data release this November which indicates further upside to the stock.
- GBA UPGRADE LAVA Therapeutics.
Last edited:
--LAVA Therapeutics N.V.(Nasdaq:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced the Company will present data demonstrating on-mechanism pharmacodynamics for LAVA-051 in the clinic during the Society for Immunotherapy of Cancer’s 37thAnnual Meeting, taking place in Boston, Massachusetts and virtually from November 8-12, 2022.
The details of the poster presentation session are as follows:
Abstract #: 686
Abstract Title: Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager (bsTCE), confirmed in the clinical setting
Session Title: Cellular Therapies + Bispecifics
Session Date:Friday, November 11, 2022
Session Time:9:00 a.m.–8:30 p.m. EST/3:00 p.m.–2:30 a.m. CET
Presenter: Benjamin Winograd, M.D., Ph.D., chief medical officer, LAVA Therapeutics
Very long presentation! Wonder if that is a typo... 9 in the morn to 8:30 at night on a Friday>>??? WTF
The details of the poster presentation session are as follows:
Abstract #: 686
Abstract Title: Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager (bsTCE), confirmed in the clinical setting
Session Title: Cellular Therapies + Bispecifics
Session Date:Friday, November 11, 2022
Session Time:9:00 a.m.–8:30 p.m. EST/3:00 p.m.–2:30 a.m. CET
Presenter: Benjamin Winograd, M.D., Ph.D., chief medical officer, LAVA Therapeutics
Very long presentation! Wonder if that is a typo... 9 in the morn to 8:30 at night on a Friday>>??? WTF